[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] # GSK plc (GSK) GSK terminates collaboration with IDEAYA Biosciences, returning rights to two clinical-stage assets, while also receiving FDA Orphan Drug Designation for risvutatug rezetecan in small-cell lung cancer. ### About GSK plc GSK plc is a multinational pharmaceutical and biotechnology company. GSK plc uses the ticker $GSK for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors. ### Insights - GSK plc (GSK) trading volume is up XXXX% from the previous week. - GSK plc (GSK) social dominance is up XXXXXX% from the previous week. - GSK plc (GSK) posts created is up XXXXX% from the previous week. - GSK plc Price hit a 52-Week high of $XXXXX for the hour - GSK plc Price hit an all time of $XXXXX for the hour ### Price: $XXXXX  [Price 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/close.tsv) GSK's stock price is near a 52-week high, supported by positive sentiment from FDA approvals and social media engagement, but recent legal disputes and concerns over Blenrep's label restrictions may introduce volatility. 24-Hour: XXXX% 7-Day: XXXX% 1-Year High: $XX on 2025-12-03 1-Year Low: $XXXXX on 2025-01-14 ### AltRank: XXXXX  [AltRank 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/alt_rank.tsv) GSK plc (GSK) is currently AltRank #1,398 based on combined combined social and market metrics Daily Average: XXX X Week: XXX -XXX X Month: XXX +437 X Months: XXX -XXX X Year: XXX +323 1-Year High: XXXXX on 2025-06-19 1-Year Low: X on 2025-02-09 ### Galaxy Score: XXXXX  [Galaxy Score 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/galaxy_score.tsv) Current Value: XXXXX Daily Average: XX X Week: XX +2 X Month: XX -X X Months: XX +25 X Year: XX -X 1-Year High: XX on 2025-05-13 1-Year Low: XX on 2025-07-03 ### Engagements: XXXXX (24h)  [Engagements 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/interactions.tsv) Current Value: XXXXX Daily Average: XXXXXX X Week: XXXXXX -XX% X Month: XXXXXXX -XX% X Months: XXXXXXXXX +28% X Year: XXXXXXXXX -XX% 1-Year High: XXXXXXX on 2025-02-05 1-Year Low: XXX on 2025-12-07 Engagements by network (24h): Reddit: XX X: XXXXX YouTube: X ### Mentions: XX (24h)  [Mentions 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/posts_active.tsv) Current Value: XX Daily Average: XXX X Week: XXX -XX% X Month: XXX -XX% X Months: XXXXX +73% X Year: XXXXX +73% 1-Year High: XXX on 2025-08-03 1-Year Low: XX on 2025-12-07 Mentions by network (24h): Reddit: X X: XXX YouTube: X ### Creators: XX (24h)  [Creators 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/contributors_active.tsv) XX unique social accounts have posts mentioning GSK plc (GSK) in the last XX hours which is up XX% from XX in the previous XX hours Daily Average: XX X Week: XX -XX% X Month: XXX -XX% X Months: XXXXX +72% X Year: XXXXX +65% 1-Year High: XXX on 2025-06-28 1-Year Low: XX on 2025-12-07 The most influential creators that mention GSK plc in the last XX hours | Creator | Rank | Followers | Posts | Engagements | | ------- | ---- | --------- | ----- | ----------- | | [@BiopharmIQ](/creator/twitter/BiopharmIQ) | X | XXXXXX | X | XXX | | [@fastmoneysource](/creator/twitter/fastmoneysource) | X | XXX | X | XXX | | [@MoneyMaker0009](/creator/twitter/MoneyMaker0009) | X | XXX | X | XX | | [@semodough](/creator/twitter/semodough) | X | XXXXXX | X | XX | | [@BioSignal](/creator/twitter/BioSignal) | X | XX | X | XX | | [@Darwin_Knows](/creator/twitter/Darwin_Knows) | X | XXX | X | XX | | [@MarcJacksonLA](/creator/twitter/MarcJacksonLA) | X | XXXXX | X | XX | | [@AponiaAnalytics](/creator/twitter/AponiaAnalytics) | X | XXXXX | X | XX | | [@MarketCap_Live](/creator/twitter/MarketCap_Live) | X | XXX | X | XX | | [@ContextAnalytic](/creator/twitter/ContextAnalytic) | XX | XXXXX | X | XX | [View More](/list/creators/gsk-plc/100) ### Sentiment: XX%  [Sentiment 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/sentiment.tsv) Current Value: XX% Daily Average: XX% X Week: XX% -XX% X Month: XX% no change X Months: XX% no change X Year: XX% +3% 1-Year High: XXX% on 2025-04-21 1-Year Low: XX% on 2025-08-26 Most Supportive Themes: - FDA Approval of Blenrep: (30%) GSK's multiple myeloma drug Blenrep has received FDA approval for specific patient groups, marking a significant regulatory milestone. - Earnings Reports and Financial Performance: (25%) GSK's recent earnings reports and financial performance are being closely watched and discussed, with revenue and EPS figures highlighted. - Partnerships and Acquisitions: (20%) GSK is actively engaging in strategic partnerships and acquisitions, such as the deal with Empirico, to expand its pipeline and market reach. Most Critical Themes: - Blenrep Label Restrictions: (40%) Despite FDA approval, Blenrep's label is narrower than anticipated, raising concerns about its near-term commercial upside and market penetration. - Pipeline Development Challenges: (35%) GSK faces ongoing challenges in its R&D pipeline, with some drug candidates like the one partnered with Alector failing in late-stage trials. ### Social Dominance: XXXXXX%  [Social Dominance 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/social_dominance.tsv) Current Value: XXXXXX% Daily Average: XXXXX% X Week: XXXXX% +0.011% X Month: XXXXXX% -XXXXXXXXXXXXXXXXXXXX% X Months: XXXXXX% -XXXXXX% X Year: XXXXXX% -XXXXX% 1-Year High: XXXXX% on 2025-01-02 1-Year Low: XXXXXX% on 2025-12-07 ### Market Dominance: XXXXX%  [Market Dominance 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/market_dominance.tsv) Current Value: XXXXX% Daily Average: X% 1-Year High: XXXX% on 2025-12-02 1-Year Low: XXXXX% on 2025-12-10 ### Market Cap: $XXXXXXXXXXXXXX  [Market Cap 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/market_cap.tsv) Current Value: $XXXXXXXXXXXXXX Daily Average: $XXXXXXXXXXXXXX X Week: $XXXXXXXXXXXXXX -$1.20% X Month: $XXXXXXXXXXXXXX +$2.10% X Months: $XXXXXXXXXXXXXX +$18% X Year: $XXXXXXXXXXXXXX +$36% 1-Year High: $XXXXXXXXXXXXXX on 2025-12-03 1-Year Low: $XXXXXXXXXXXXXX on 2025-01-14 ### Top GSK plc Social Posts Top posts by engagements in the last XX hours *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "GreetEat Corp. (OTC: $GEAT) Sees Surge in User Growth Across and Accelerates AI-Driven Expansion $PG $MRK $MYL $VRTX $BIIB $BMY $JNJ $AZN $REGN $JNJ $PFE $GSK $LLY $ABT $SNY $NVO $NVS $WBA" [X Link](https://x.com/MoneyMaker0009/status/1998741566471446870) [@MoneyMaker0009](/creator/x/MoneyMaker0009) 2025-12-10T13:08Z XXX followers, XX engagements "BREAKING: GSK ($GSK) has officially terminated its collaboration with IDEAYA Biosciences ($IDYA) returning full global rights to two clinical-stage assets. The returned programs: IDE275 (Werner Helicase) IDE705 (Pol Theta) This marks the final dissolution of their $3.1B partnership from 2020 (MAT2A was returned previously). GSK is effectively exiting early-stage synthetic lethality. The Investment View: The market typically sells on "Pharma Exits" assuming the data is bad. However IDEAYA's primary value driver is Darovasertib (Uveal Melanoma) not these assets. With major Phase 2/3 data for" [X Link](https://x.com/BioSignal/status/1998708527033102641) [@BioSignal](/creator/x/BioSignal) 2025-12-10T10:57Z XX followers, XX engagements "#tradingfloorai #GSK #FDA GSK plc announced that its investigational antibody-drug conjugate risvutatug rezetecan (GSK227) has received Orphan Drug Designation (ODD) from the US FDA for treating small-cell lung cancer (SCLC). This designation is supported by early clinical data showing durable responses in patients with extensive-stage SCLC (ES-SCLC) a particularly aggressive form of the disease with limited treatment options and poor prognosis. Risvutatug rezetecan targets B7-H3 a protein overexpressed in various solid tumors and is being developed for multiple cancer types including lung" [X Link](https://x.com/tradingfloorai/status/1998654346729345152) [@tradingfloorai](/creator/x/tradingfloorai) 2025-12-10T07:21Z 1928 followers, XXX engagements "BREAKING: Novartis ($NVS) just signed a massive $1.75B deal with Relation Therapeutics to hunt for new dermatology targets. The "Alpha" isn't just the dollar figureit's the technology. Relation uses a "Lab-in-the-Loop" AI platform and is backed by Nvidia ($NVDA) and $GSK. Big Pharma is officially paying a premium to outsource discovery to the AI-native biotechs. Deal terms: $55M Upfront / $1.7B Milestones. $NVS $NVDA $GSK $XBI $IBB" [X Link](https://x.com/BioSignal/status/1998581189754630327) [@BioSignal](/creator/x/BioSignal) 2025-12-10T02:31Z XX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
GSK plc (GSK)
GSK terminates collaboration with IDEAYA Biosciences, returning rights to two clinical-stage assets, while also receiving FDA Orphan Drug Designation for risvutatug rezetecan in small-cell lung cancer.
About GSK plc
GSK plc is a multinational pharmaceutical and biotechnology company.
GSK plc uses the ticker $GSK for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- GSK plc (GSK) trading volume is up XXXX% from the previous week.
- GSK plc (GSK) social dominance is up XXXXXX% from the previous week.
- GSK plc (GSK) posts created is up XXXXX% from the previous week.
- GSK plc Price hit a 52-Week high of $XXXXX for the hour
- GSK plc Price hit an all time of $XXXXX for the hour
Price: $XXXXX
Price 24-Hour Time-Series Raw Data
GSK's stock price is near a 52-week high, supported by positive sentiment from FDA approvals and social media engagement, but recent legal disputes and concerns over Blenrep's label restrictions may introduce volatility.
24-Hour: XXXX% 7-Day: XXXX%
1-Year High: $XX on 2025-12-03
1-Year Low: $XXXXX on 2025-01-14
AltRank: XXXXX
AltRank 24-Hour Time-Series Raw Data
GSK plc (GSK) is currently AltRank #1,398 based on combined combined social and market metrics
Daily Average: XXX
X Week: XXX -XXX
X Month: XXX +437
X Months: XXX -XXX
X Year: XXX +323
1-Year High: XXXXX on 2025-06-19
1-Year Low: X on 2025-02-09
Galaxy Score: XXXXX
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX +2
X Month: XX -X
X Months: XX +25
X Year: XX -X
1-Year High: XX on 2025-05-13
1-Year Low: XX on 2025-07-03
Engagements: XXXXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXXX
X Week: XXXXXX -XX%
X Month: XXXXXXX -XX%
X Months: XXXXXXXXX +28%
X Year: XXXXXXXXX -XX%
1-Year High: XXXXXXX on 2025-02-05
1-Year Low: XXX on 2025-12-07
Engagements by network (24h): Reddit: XX X: XXXXX YouTube: X
Mentions: XX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
X Week: XXX -XX%
X Month: XXX -XX%
X Months: XXXXX +73%
X Year: XXXXX +73%
1-Year High: XXX on 2025-08-03
1-Year Low: XX on 2025-12-07
Mentions by network (24h): Reddit: X X: XXX YouTube: X
Creators: XX (24h)
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning GSK plc (GSK) in the last XX hours which is up XX% from XX in the previous XX hours
Daily Average: XX
X Week: XX -XX%
X Month: XXX -XX%
X Months: XXXXX +72%
X Year: XXXXX +65%
1-Year High: XXX on 2025-06-28
1-Year Low: XX on 2025-12-07
The most influential creators that mention GSK plc in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @BiopharmIQ | X | XXXXXX | X | XXX |
| @fastmoneysource | X | XXX | X | XXX |
| @MoneyMaker0009 | X | XXX | X | XX |
| @semodough | X | XXXXXX | X | XX |
| @BioSignal | X | XX | X | XX |
| @Darwin_Knows | X | XXX | X | XX |
| @MarcJacksonLA | X | XXXXX | X | XX |
| @AponiaAnalytics | X | XXXXX | X | XX |
| @MarketCap_Live | X | XXX | X | XX |
| @ContextAnalytic | XX | XXXXX | X | XX |
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% -XX%
X Month: XX% no change
X Months: XX% no change
X Year: XX% +3%
1-Year High: XXX% on 2025-04-21
1-Year Low: XX% on 2025-08-26
Most Supportive Themes:
- FDA Approval of Blenrep: (30%) GSK's multiple myeloma drug Blenrep has received FDA approval for specific patient groups, marking a significant regulatory milestone.
- Earnings Reports and Financial Performance: (25%) GSK's recent earnings reports and financial performance are being closely watched and discussed, with revenue and EPS figures highlighted.
- Partnerships and Acquisitions: (20%) GSK is actively engaging in strategic partnerships and acquisitions, such as the deal with Empirico, to expand its pipeline and market reach.
Most Critical Themes:
- Blenrep Label Restrictions: (40%) Despite FDA approval, Blenrep's label is narrower than anticipated, raising concerns about its near-term commercial upside and market penetration.
- Pipeline Development Challenges: (35%) GSK faces ongoing challenges in its R&D pipeline, with some drug candidates like the one partnered with Alector failing in late-stage trials.
Social Dominance: XXXXXX%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXX%
Daily Average: XXXXX%
X Week: XXXXX% +0.011%
X Month: XXXXXX% -XXXXXXXXXXXXXXXXXXXX%
X Months: XXXXXX% -XXXXXX%
X Year: XXXXXX% -XXXXX%
1-Year High: XXXXX% on 2025-01-02
1-Year Low: XXXXXX% on 2025-12-07
Market Dominance: XXXXX%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: X%
1-Year High: XXXX% on 2025-12-02
1-Year Low: XXXXX% on 2025-12-10
Market Cap: $XXXXXXXXXXXXXX
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXXX -$1.20%
X Month: $XXXXXXXXXXXXXX +$2.10%
X Months: $XXXXXXXXXXXXXX +$18%
X Year: $XXXXXXXXXXXXXX +$36%
1-Year High: $XXXXXXXXXXXXXX on 2025-12-03
1-Year Low: $XXXXXXXXXXXXXX on 2025-01-14
Top GSK plc Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"GreetEat Corp. (OTC: $GEAT) Sees Surge in User Growth Across and Accelerates AI-Driven Expansion $PG $MRK $MYL $VRTX $BIIB $BMY $JNJ $AZN $REGN $JNJ $PFE $GSK $LLY $ABT $SNY $NVO $NVS $WBA"
X Link @MoneyMaker0009 2025-12-10T13:08Z XXX followers, XX engagements
"BREAKING: GSK ($GSK) has officially terminated its collaboration with IDEAYA Biosciences ($IDYA) returning full global rights to two clinical-stage assets. The returned programs: IDE275 (Werner Helicase) IDE705 (Pol Theta) This marks the final dissolution of their $3.1B partnership from 2020 (MAT2A was returned previously). GSK is effectively exiting early-stage synthetic lethality. The Investment View: The market typically sells on "Pharma Exits" assuming the data is bad. However IDEAYA's primary value driver is Darovasertib (Uveal Melanoma) not these assets. With major Phase 2/3 data for"
X Link @BioSignal 2025-12-10T10:57Z XX followers, XX engagements
"#tradingfloorai #GSK #FDA GSK plc announced that its investigational antibody-drug conjugate risvutatug rezetecan (GSK227) has received Orphan Drug Designation (ODD) from the US FDA for treating small-cell lung cancer (SCLC). This designation is supported by early clinical data showing durable responses in patients with extensive-stage SCLC (ES-SCLC) a particularly aggressive form of the disease with limited treatment options and poor prognosis. Risvutatug rezetecan targets B7-H3 a protein overexpressed in various solid tumors and is being developed for multiple cancer types including lung"
X Link @tradingfloorai 2025-12-10T07:21Z 1928 followers, XXX engagements
"BREAKING: Novartis ($NVS) just signed a massive $1.75B deal with Relation Therapeutics to hunt for new dermatology targets. The "Alpha" isn't just the dollar figureit's the technology. Relation uses a "Lab-in-the-Loop" AI platform and is backed by Nvidia ($NVDA) and $GSK. Big Pharma is officially paying a premium to outsource discovery to the AI-native biotechs. Deal terms: $55M Upfront / $1.7B Milestones. $NVS $NVDA $GSK $XBI $IBB"
X Link @BioSignal 2025-12-10T02:31Z XX followers, XX engagements